Executive Chairman and President of Botanix, Vince Ippolito, commented: “........
“It was apparent that outside GW Pharmaceuticals’ FDA approved Epidiolex epilepsy product, Botanix
has the most mature development pipeline of any other cannabinoid company featured at the iCDP
Summit. Our rapid development approach has distinguished us from our peers, many of whom have
been in development for 5 to 15 years and are only now starting human studies for the first time.”
Ann: Botanix Presents at International Cannabinoid Summit, page-2
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $456.7M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 30.5¢ | 29.0¢ | $1.147M | 3.861M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 589472 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 39319 | 2 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
29.0¢ |
Change
0.000 ( 1.13 %) |
||||
| Open | High | Low | Volume | ||
| 29.5¢ | 30.5¢ | 29.0¢ | 2638633 | ||
| Last updated 15.59pm 03/06/2024 ? | |||||
| BOT (ASX) Chart |